Antares Pharma, Inc. (NYSE Amex: AIS) today announced that it will release its second quarter 2010 financial results after the market closes on Thursday, August 12, 2010, and host a conference call shortly thereafter at 4:30 p.m. ET (Eastern Time) to discuss the results. Paul K. Wotton, Ph.D., President and Chief Executive Officer, and Robert F. Apple, EVP, CFO and President of the Parenteral Products Division, will host the call.
Interested parties may participate in the conference call by dialing 800-762-8779 (US) or 480-629-9771 (international), 5-10 minutes prior to the start of the call. A replay of the conference call will be available approximately 2 hours after the call’s conclusion through 12:00 p.m. ET (Eastern Time) on August 26, 2010 by dialing 800-406-7325 (US) or 303-590-3030 (international), and entering the reservation # 4333008. An audio web cast and archive of the conference call will also be available under the investor relations section of the Antares Web site at www.antarespharma.com.
About Antares Pharma
Antares Pharma focuses on self-injection delivery technologies and topical gel-based pharmaceutical products. The Company's subcutaneous and intramuscular injection technology platforms include VIBEXTM disposable pressure-assisted auto injectors, ValeoTM/VisionTM reusable needle-free injectors, and disposable multi-use pen injectors. In the injector area, Antares Pharma has a multi-product deal with Teva Pharmaceutical Industries, Ltd that includes Tev-Tropin(R) human growth hormone and a partnership with Ferring Pharmaceuticals. In the gel-based area, the Company's lead product candidate is Anturol(R) an oxybutynin ATDTM gel for the treatment of OAB (overactive bladder). Antares also has a partnership with BioSante that includes LibiGel(R) (transdermal testosterone gel) in Phase 3 clinical development for the treatment of female sexual dysfunction (FSD), and Elestrin(R) (estradiol gel) indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, and currently marketed in the U.S. Antares Pharma has corporate headquarters in Ewing, New Jersey, with subsidiaries performing research, development and product commercialization activities in Minneapolis, Minnesota and Muttenz, Switzerland.